Advanced solution for male androgenetic alopecia

Densita MF Solution, launched by Regaliz Medicare, contains Redensyl, Minoxidil 5% and Finasteride 0.1%. Redensyl is a patented molecule targeting ORSc and dermal papilla cells in fibroblasts, which activates the cell division and promotes the growth of hair follicle. Redensyl has proven its clinical efficacy in various age groups and shows better results than hair transplant surgeries. Redensyl, in synergy with Minoxidil and Finasteride, accelerates hair growth and stops hair loss. Multiple studies show Minoxidil and Finasteride topical combination having better results than monotherapy of Minoxidil. Topical Finasteride has a better safety profile compared to oral Finasteride and shows better results in clinical trials. Densita MF solution is alcohol-free and contains penetration boosters that help in faster absorption. It also comes with an ease of application pack (pump as well as dropper provided in the pack). Regaliz Medicare, with its reinventing therapies, continues to offer innovative, efficacious and quality products.